Innovent Biologics Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Innovent Biologics is forecast to grow earnings and revenue by 58.7% and 22.1% per annum respectively. EPS is expected to grow by 60% per annum. Return on equity is forecast to be 15.9% in 3 years.
Wichtige Informationen
58.7%
Wachstumsrate der Gewinne
60.0%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 41.8% |
Wachstumsrate der Einnahmen | 22.1% |
Zukünftige Eigenkapitalrendite | 15.9% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 03 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why
Jun 14Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 01There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump
Feb 28Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?
Jan 12Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues
Dec 25An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued
Sep 11Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?
Jun 04Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price
May 14Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate
Dec 27Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 13,414 | 1,353 | 1,300 | 1,764 | 28 |
12/31/2025 | 10,496 | 105 | -308 | 506 | 30 |
12/31/2024 | 8,092 | -773 | -1,327 | -695 | 30 |
6/30/2024 | 7,457 | -1,281 | -969 | 555 | N/A |
3/31/2024 | 6,831 | -1,155 | -1,102 | 351 | N/A |
12/31/2023 | 6,206 | -1,028 | -1,234 | 148 | N/A |
9/30/2023 | 5,612 | -1,198 | -2,241 | -794 | N/A |
6/30/2023 | 5,018 | -1,368 | -3,249 | -1,735 | N/A |
3/31/2023 | 4,787 | -1,774 | -3,267 | -1,827 | N/A |
12/31/2022 | 4,556 | -2,179 | -3,284 | -1,919 | N/A |
9/30/2022 | 4,562 | -2,427 | -3,507 | -1,867 | N/A |
6/30/2022 | 4,568 | -2,676 | -3,729 | -1,816 | N/A |
3/31/2022 | 4,419 | -2,702 | -3,801 | -1,920 | N/A |
12/31/2021 | 4,270 | -2,729 | -3,872 | -2,025 | N/A |
9/30/2021 | 4,536 | -2,061 | -2,660 | -1,302 | N/A |
6/30/2021 | 4,801 | -1,394 | -1,447 | -580 | N/A |
3/31/2021 | 4,323 | -1,196 | -1,138 | -444 | N/A |
12/31/2020 | 3,844 | -998 | -829 | -308 | N/A |
9/30/2020 | 2,765 | -1,306 | -1,307 | -900 | N/A |
6/30/2020 | 1,686 | -1,614 | -1,784 | -1,492 | N/A |
3/31/2020 | 1,367 | -1,667 | -1,907 | -1,578 | N/A |
12/31/2019 | 1,048 | -1,720 | -2,030 | -1,664 | N/A |
9/30/2019 | 699 | -4,125 | -1,988 | -1,625 | N/A |
6/30/2019 | 351 | -6,530 | -1,945 | -1,586 | N/A |
3/31/2019 | 180 | -6,151 | -1,635 | -1,299 | N/A |
12/31/2018 | 9 | -5,771 | -1,325 | -1,012 | N/A |
9/30/2018 | 39 | -3,041 | -1,046 | -799 | N/A |
6/30/2018 | 69 | -311 | -767 | -587 | N/A |
3/31/2018 | 72 | -437 | N/A | -540 | N/A |
12/31/2017 | 75 | -562 | N/A | -492 | N/A |
12/31/2016 | 29 | -504 | N/A | -363 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1801 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Ertrag vs. Markt: 1801 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: 1801 is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: 1801's revenue (22.1% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Hohe Wachstumseinnahmen: 1801's revenue (22.1% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1801's Return on Equity is forecast to be low in 3 years time (15.9%).